文献速递其他结缔组织病

靶向IL1RAP联合抑制IL-1、IL-33和IL-36信号可改善系统性硬化症临床前模型中的皮肤和肺纤维化

Combined inhibition of IL-1, IL-33 and IL-36 signalling by targeting IL1RAP ameliorates skin and lung fibrosis in preclinical models of systemic sclerosis.
PubMed 文献 · Ann Rheum Dis · 2024-08-27

本研究通过公共RNA测序数据挖掘和成像质谱流式检测IL1RAP相关信号分子在SSc皮肤中的表达,并在三种小鼠模型(硬化性慢性移植物抗宿主病、博来霉素诱导真皮纤维化、拓扑异构酶I诱导纤维化)中评估抗IL1RAP抗体疗效。结果显示SSc皮肤中IL1RAP及IL1RAP相关信号分子在mRNA和蛋白水平上调,抗IL1RAP抗体在体外完全阻断人成纤维细胞和内皮细胞对IL-1、IL-33和IL-36的反应,并在三种模型中减轻真皮和肺纤维化。

要点

  • SSc皮肤中IL1RAP及IL1RAP相关信号分子在mRNA和蛋白水平较正常皮肤上调。
  • 抗IL1RAP抗体在体外完全阻断人成纤维细胞和内皮细胞对IL-1、IL-33和IL-36的反应。
  • 抗IL1RAP抗体在三种小鼠模型中减轻真皮和肺纤维化,RNAseq显示影响炎症和纤维化相关过程。

核心结论

  • 本研究首次提供靶向IL1RAP治疗SSc具有治疗获益的证据。
  • 作者认为研究发现具有高转化潜力,因为抗IL1RAP抗体CAN10近期已进入一期临床试验。

研究设计与样本

  • 研究通过公共RNA测序数据挖掘和成像质谱流式检测IL1RAP相关信号分子表达。
  • 在三种互补小鼠模型中评估治疗性给药抗IL1RAP抗体的疗效:硬化性慢性移植物抗宿主病、博来霉素诱导真皮纤维化模型和拓扑异构酶I诱导纤维化。

主要发现

  • SSc皮肤较正常皮肤在mRNA和蛋白水平显示IL1RAP及IL1RAP相关信号分子上调。
  • IL-1、IL-33和IL-36均调控与SSc不同病理生理过程相关的不同基因集。
  • 抗IL1RAP抗体处理在体外完全阻断人成纤维细胞和内皮细胞对IL-1、IL-33和IL-36的反应。
  • 抗IL1RAP抗体治疗减轻cGvHD诱导、博来霉素诱导和拓扑异构酶诱导纤维化模型中的真皮和肺纤维化。
  • RNAseq分析显示IL1RAP抑制影响多种与炎症和纤维化相关的过程,这些过程在人类SSc皮肤中也失调。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The interleukin (IL)-1 receptor accessory protein (IL1RAP) is an essential coreceptor required for signalling through the IL-1, IL-33 and IL-36 receptors. Here, we investigate the antifibrotic potential of the combined inhibition of these cytokines by an anti-IL1RAP antibody to provide a scientific background for clinical development in systemic sclerosis (SSc). METHODS: The expression of IL1RAP-associated signalling molecules was determined by data mining of publicly available RNA sequencing (RNAseq) data as well as by imaging mass cytometry. The efficacy of therapeutic dosing of anti-IL1RAP antibodies was determined in three complementary mouse models: sclerodermatous chronic graft-versus-host disease (cGvHD), bleomycin-induced dermal fibrosis model and topoisomerase-I (topo)-induced fibrosis. RESULTS: SSc skin showed upregulation of IL1RAP and IL1RAP-related signalling molecules on mRNA and protein level compared with normal skin. IL-1, IL-33 and IL-36 all regulate distinct gene sets related to different pathophysiological processes in SSc. The responses of human fibroblasts and endothelial cells to IL-1, IL-33 and IL-36 were completely blocked by treatment with an anti-IL1RAP antibody in vitro. Moreover, anti-IL1RAP antibody treatment reduced dermal and pulmonary fibrosis in cGvHD-induced, bleomycin-induced and topoisomerase-induced fibrosis. Importantly, RNAseq analyses revealed effects of IL1RAP inhibition on multiple processes related to inflammation and fibrosis that are also deregulated in human SSc skin. CONCLUSION: This study provides the first evidence for the therapeutic benefits of targeting IL1RAP in SSc. Our findings have high translational potential as the anti-IL1RAP antibody CAN10 has recently entered a phase one clinical trial.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Grönberg C, Rattik S, Tran-Manh C, et al. Combined inhibition of IL-1, IL-33 and IL-36 signalling by targeting IL1RAP ameliorates skin and lung fibrosis in preclinical models of systemic sclerosis. Ann Rheum Dis. 2024. PMID: 38594058. doi:10.1136/ard-2023-225158

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。